Bristol Myers Squibb and Pfizer to Make Eliquis® (Apixaban) Available via Mark Cuban Cost Plus Drug Company

Key Takeaways

• Eliquis listed on Cost Plus Drugs for $345 per month
• Collaboration launches April 27, 2026, targeting cash‑pay patients
• BMS‑Pfizer aims to increase transparency and lower out‑of‑pocket costs
• Eliquis 30‑day supply priced below typical insurance copays
• Estimated $3 billion healthcare savings per 100k patients

Pulse Analysis

The pharmaceutical landscape is increasingly embracing direct‑to‑consumer models as patients demand price transparency and predictable out‑of‑pocket costs. Cost Plus Drugs, founded by entrepreneur Mark Cuban, has built a reputation for offering generic and branded medicines at a flat markup, bypassing traditional pharmacy benefit managers. By partnering with this platform, the BMS‑Pfizer Alliance taps into a growing segment of cash‑pay consumers who are frustrated by opaque insurance pricing and high copays, positioning Eliquis as a flagship example of this new distribution strategy.

Eliquis, the market‑leading oral anticoagulant for atrial fibrillation, deep‑vein thrombosis and pulmonary embolism, commands a substantial share of the $10 billion U.S. anticoagulant market. The $345 monthly price translates to roughly $11,500 annually, markedly lower than typical insured copays that can exceed $50 per day. Beyond affordability, the drug’s clinical profile—demonstrated to generate about $3 billion in healthcare‑cost savings per 100,000 patients—reinforces its value proposition. By offering a fixed cash price, the alliance not only eases financial barriers for patients but also showcases a cost‑effectiveness narrative that could influence payer negotiations and formulary decisions.

For the broader industry, this collaboration underscores a strategic pivot toward alternative sales channels that reduce reliance on traditional pharmacy networks. As more manufacturers explore similar arrangements, competition may intensify, prompting insurers to revisit rebate structures and price‑setting mechanisms. Regulators will likely monitor these models for compliance with pharmacy‑dispensing laws, while patients stand to benefit from increased choice and price clarity. The success of Eliquis on Cost Plus Drugs could serve as a template for other high‑volume specialty drugs seeking to balance revenue goals with patient‑centric pricing.